Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform Read more
AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval Read more
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed Read more
Navid Gholampour
Navid has over a decade of experience in Life Sciences recruitment. He partners with leaders to build patient-focused and innovative organisation
